The BTK/PI3K/BRD4 axis inhibitor SRX3262 overcomes Ibrutinib resistance in mantle cell lymphoma

Dhananjaya Pal; Kendra R. Vann; Shweta Joshi; Namood E. Sahar; Guillermo A. Morales; Dalia El-Gamal; Tatiana G. Kutateladze; Donald L. Durden

iScience (Sep 2021)

The BTK/PI3K/BRD4 axis inhibitor SRX3262 overcomes Ibrutinib resistance in mantle cell lymphoma

Dhananjaya Pal,
Kendra R. Vann,
Shweta Joshi,
Namood E. Sahar,
Guillermo A. Morales,
Dalia El-Gamal,
Tatiana G. Kutateladze,
Donald L. Durden

Affiliations

Dhananjaya Pal: Division of Hematology and Oncology, Department of Pediatrics, Moores Cancer Center, University of California San Diego, La Jolla, CA, USA; Department of Pediatrics Computational Chemistry, College of Medicine University of Nebraska Medical Center, Omaha, NE, USA
Kendra R. Vann: Department of Pharmacology, University of Colorado School of Medicine, Aurora, CO, USA
Shweta Joshi: Division of Hematology and Oncology, Department of Pediatrics, Moores Cancer Center, University of California San Diego, La Jolla, CA, USA
Namood E. Sahar: Division of Hematology and Oncology, Department of Pediatrics, Moores Cancer Center, University of California San Diego, La Jolla, CA, USA; Department of Pediatrics Computational Chemistry, College of Medicine University of Nebraska Medical Center, Omaha, NE, USA
Guillermo A. Morales: SignalRx Pharmaceuticals, Inc., Cumming, GA, USA
Dalia El-Gamal: Eppley Institute for Research in Cancer and Allied Diseases, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA
Tatiana G. Kutateladze: Department of Pharmacology, University of Colorado School of Medicine, Aurora, CO, USA; Corresponding author
Donald L. Durden: Division of Hematology and Oncology, Department of Pediatrics, Moores Cancer Center, University of California San Diego, La Jolla, CA, USA; Department of Pediatrics Computational Chemistry, College of Medicine University of Nebraska Medical Center, Omaha, NE, USA; SignalRx Pharmaceuticals, Inc., Cumming, GA, USA; Corresponding author

Journal volume & issue: Vol. 24, no. 9
p. 102931

Abstract

Read online

Summary: Mantle cell lymphoma (MCL) is an aggressive subtype of non-Hodgkin's lymphoma and one of the most challenging blood cancers to combat due to frequent relapse after treatment. Here, we developed the first-in-class BTK/PI3K/BRD4 axis inhibitor SRX3262, which simultaneously blocks three interrelated MCL driver pathways – BTK, PI3K-AKT-mTOR and MYC. SRX3262 concomitantly binds to BTK, PI3K, and BRD4, exhibits potent in vitro and in vivo activity against MCL, and overcomes the Ibrutinib resistance resulting from the BTK-C481S mutation. Our results reveal that SRX3262 inhibits IgM-induced BTK and AKT phosphorylation and abrogates binding of BRD4 to MYC loci. SRX3262 promotes c-MYC destabilization, induces cell cycle arrest and apoptosis, and shows antitumor activity in in vivo xenograft models. Together, our study provides mechanistic insights and rationale for the use of the triple BTK/PI3K/BRD4 activity inhibitors as a new approach to treat MCL.

Published in iScience

ISSN: 2589-0042 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Science
Website: http://www.cell.com/iscience/home

About the journal

Abstract

Keywords